Get In Touch with Post Translational Medicines
Please tell us a little bit about yourself and why you'd like to get connected. Post Translational Medicines + SOSV will follow up with you via email.
Led by Bryan Ngo, PhD., (Altos Labs, Weill Cornell Medicine, Memorial Sloan Kettering), Post Translational Medicines (PTM) has half their round in the bank already. With an all-star team and an Advisor group with Nobel Prize winners, PTM is focused on a key feature of neurodegeneration, the accumulation and aggregation of waste proteins – the first of many hallmarks of aging that the company will pursue.
PTM’s first target is the enzyme that controls the pH of lysosomes. In aging cells, the enzyme takes a different shape, and the pH is not maintained. Cellular waste stops being secreted and cellular function falters. PTM’s cutting edge proteomics platform uncovered where to bind this target, how to bind this target – and how to make the aged enzyme isoform to reshape itself into a fully functional pillar of cellular health. PTM’s drug development efforts have them already at a very efficacious tool compound that binds very well to the aged isoform and repairs lysosomal function, while completely leaving alone the healthy isoform and healthy cells. With this round, they will advance the program to lead stage and deliver a biological data package covering both fundamental aging biology and cutting-edge disease models.
Post Translational Medicines’ unique biological data has seen strong inbound interest from pharma for their drug discovery value, from cosmetics companies for their anti-aging product lines, and from leading AI foundation labs – because Post Translational Medicines’ new source of in-cell protein data could be the foundation of a whole new generation of alphafold models.

Expands the druggable universe from 20,000 proteins to 6 million proteoforms
Post Translational Medicines is providing the 'Ground Truth' data that AlphaFold 3 is currently missing.
Please tell us a little bit about yourself and why you'd like to get connected. Post Translational Medicines + SOSV will follow up with you via email.
No Offer, Solicitation, Advice, or Recommendation
Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.